Robin Hallett
Overview
Explore the profile of Robin Hallett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ladumor Y, Seong B, Hallett R, Valencia-Sama I, Adderley T, Wang Y, et al.
Mol Cancer Res
. 2022 Feb;
20(6):895-908.
PMID: 35190818
Implications: This newly identified link between VDR signaling and the Hippo pathway could inform treatment strategies for metastatic neuroblastoma.
2.
Manoranjan B, Venugopal C, Bakhshinyan D, Adile A, Richards L, Kameda-Smith M, et al.
Nat Commun
. 2020 Aug;
11(1):4323.
PMID: 32859895
Medulloblastoma (MB) is defined by four molecular subgroups (Wnt, Shh, Group 3, Group 4) with Wnt MB having the most favorable prognosis. Since prior reports have illustrated the antitumorigenic role...
3.
Bakhshinyan D, Venugopal C, Adile A, Garg N, Manoranjan B, Hallett R, et al.
Oncogene
. 2018 Oct;
38(10):1702-1716.
PMID: 30348991
Medulloblastoma (MB) is the most frequent malignant pediatric brain tumor, representing 20% of newly diagnosed childhood central nervous system malignancies. Although advances in multimodal therapy yielded a 5-year survivorship of...
4.
Seong B, Fathers K, Hallett R, Yung C, Stein L, Mouaaz S, et al.
Cancer Res
. 2016 Dec;
77(3):696-706.
PMID: 27899382
Metastatic relapse is the major cause of death in pediatric neuroblastoma, where there remains a lack of therapies to target this stage of disease. To understand the molecular mechanisms mediating...
5.
Manoranjan B, Mahendram S, Almenawer S, Venugopal C, McFarlane N, Hallett R, et al.
Acta Neuropathol Commun
. 2016 Nov;
4(1):125.
PMID: 27894339
Classified as benign central nervous system (CNS) tumors, pituitary adenomas account for 10% of diagnosed intracranial neoplasms. Although surgery is often curative, patients with invasive macroadenomas continue to experience significant...
6.
Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, et al.
Oncotarget
. 2015 Aug;
6(29):27461-77.
PMID: 26314961
Brain metastases (BM) represent the most common tumor to affect the adult central nervous system. Despite the increasing incidence of BM, likely due to consistently improving treatment of primary cancers,...
7.
Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi M, et al.
Clin Cancer Res
. 2015 Jul;
21(23):5324-37.
PMID: 26152745
Purpose: Clonal evolution of cancer may be regulated by determinants of stemness, specifically self-renewal, and current therapies have not considered how genetic perturbations or properties of stemness affect such functional...
8.
McGray A, Hallett R, Bernard D, Swift S, Zhu Z, Teoderascu F, et al.
Mol Ther
. 2013 Nov;
22(1):206-18.
PMID: 24196579
Despite clear evidence of immunogenicity, cancer vaccines only provide a modest clinical benefit. To evaluate the mechanisms that limit tumor regression following vaccination, we have investigated the weak efficacy of...
9.
McGray A, Bernard D, Hallett R, Kelly R, Jha M, Gregory C, et al.
Oncoimmunology
. 2012 Jul;
1(4):419-431.
PMID: 22754760
We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current study, an agonist...